NO983917L - Anvendelse av IL-7 for behandling av autoimmune sykdommer og sµrlig insulinavhengig diabetes mellitus - Google Patents

Anvendelse av IL-7 for behandling av autoimmune sykdommer og sµrlig insulinavhengig diabetes mellitus

Info

Publication number
NO983917L
NO983917L NO983917A NO983917A NO983917L NO 983917 L NO983917 L NO 983917L NO 983917 A NO983917 A NO 983917A NO 983917 A NO983917 A NO 983917A NO 983917 L NO983917 L NO 983917L
Authority
NO
Norway
Prior art keywords
treatment
diabetes mellitus
autoimmune diseases
dependent diabetes
especially insulin
Prior art date
Application number
NO983917A
Other languages
English (en)
Other versions
NO321569B1 (no
NO983917D0 (no
Inventor
Jean-Fran Ois Bach
Jean-Marc Gombert
Andru Herbelin
Michel Morre
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NO983917D0 publication Critical patent/NO983917D0/no
Publication of NO983917L publication Critical patent/NO983917L/no
Publication of NO321569B1 publication Critical patent/NO321569B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2046IL-7
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/46433Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
NO19983917A 1996-02-28 1998-08-26 Anvendelse av IL-7 for behandling av en autoimmun sykdom samt fremgangsmate for fremstilling av et farmasoytisk preparat. NO321569B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9602501A FR2745185B1 (fr) 1996-02-28 1996-02-28 Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
PCT/FR1997/000343 WO1997031648A1 (fr) 1996-02-28 1997-02-26 Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant

Publications (3)

Publication Number Publication Date
NO983917D0 NO983917D0 (no) 1998-08-26
NO983917L true NO983917L (no) 1998-10-28
NO321569B1 NO321569B1 (no) 2006-06-06

Family

ID=9489676

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19983917A NO321569B1 (no) 1996-02-28 1998-08-26 Anvendelse av IL-7 for behandling av en autoimmun sykdom samt fremgangsmate for fremstilling av et farmasoytisk preparat.

Country Status (13)

Country Link
US (2) US6713053B1 (no)
EP (1) EP0883406B1 (no)
JP (1) JP3138481B2 (no)
AT (1) ATE264112T1 (no)
AU (1) AU1929397A (no)
BR (1) BR9707776A (no)
DE (1) DE69728654T2 (no)
DK (1) DK0883406T3 (no)
ES (1) ES2217396T3 (no)
FR (1) FR2745185B1 (no)
NO (1) NO321569B1 (no)
PT (1) PT883406E (no)
WO (1) WO1997031648A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
TWI552760B (zh) 2010-02-24 2016-10-11 雷那特神經科學股份有限公司 拮抗劑抗-il-7受體抗體及方法
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
US10351824B2 (en) 2011-12-12 2019-07-16 Cell Medica Limited Process of expanding T cells
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
US10759863B2 (en) 2013-09-05 2020-09-01 Sanford Burnham Prebys Medical Discovery Institute Modulation of γδ T cells
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant

Also Published As

Publication number Publication date
US6713053B1 (en) 2004-03-30
ES2217396T3 (es) 2004-11-01
FR2745185B1 (fr) 1998-05-15
NO321569B1 (no) 2006-06-06
NO983917D0 (no) 1998-08-26
DE69728654D1 (de) 2004-05-19
JPH11508605A (ja) 1999-07-27
DE69728654T2 (de) 2005-03-24
DK0883406T3 (da) 2004-08-02
EP0883406B1 (fr) 2004-04-14
ATE264112T1 (de) 2004-04-15
WO1997031648A1 (fr) 1997-09-04
FR2745185A1 (fr) 1997-08-29
BR9707776A (pt) 1999-07-27
PT883406E (pt) 2004-08-31
US20040180037A1 (en) 2004-09-16
AU1929397A (en) 1997-09-16
JP3138481B2 (ja) 2001-02-26
EP0883406A1 (fr) 1998-12-16

Similar Documents

Publication Publication Date Title
ATE347585T1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
DE3680368D1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
NO20045460L (no) Behandling av T-cellemedierte autoimmune forstyrrelser
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
DE60118723D1 (de) Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten
DE69433820D1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
DE68928069D1 (de) Anti-T-Zell Rezeptordeterminanten zur Behandlung von Autoimmunkrankheiten
DE122007000002I1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
DE69531098D1 (de) Piperidine und pyrrolidine
DE69425246T2 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
DE3763851D1 (de) System zur arzneistoffabgabe mit erhoehter bioakzeptanz.
NO983917L (no) Anvendelse av IL-7 for behandling av autoimmune sykdommer og sµrlig insulinavhengig diabetes mellitus
ATE242316T1 (de) Neurale transplantation durch verwendung von pluripotenten neuroepithelzellen
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
ATE94764T1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung.
PT841939E (pt) Agentes terapeuticos e doencas auto-imunes
DE69534024D1 (de) Peptide und pharmazeutische zusammensetzungen, die diese enthalten
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
ATE254595T1 (de) 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten
IL99940A0 (en) Beta-galactoside binding proteins,methods for the production thereof,and pharmaceutical compositions containing the same
AU7718796A (en) 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus
TR199901385T2 (xx) Piperidin t�revleri.
DE69731284D1 (de) Verwendung Von Coxiella Bakterien zur Behandlung von Autoimmunkrankheiten

Legal Events

Date Code Title Description
MK1K Patent expired